BR112018012903A2 - fármaco compreendendo aripiprazol e cilostazol - Google Patents

fármaco compreendendo aripiprazol e cilostazol

Info

Publication number
BR112018012903A2
BR112018012903A2 BR112018012903A BR112018012903A BR112018012903A2 BR 112018012903 A2 BR112018012903 A2 BR 112018012903A2 BR 112018012903 A BR112018012903 A BR 112018012903A BR 112018012903 A BR112018012903 A BR 112018012903A BR 112018012903 A2 BR112018012903 A2 BR 112018012903A2
Authority
BR
Brazil
Prior art keywords
cilostazol
aripiprazole
drug
dementia
prevention
Prior art date
Application number
BR112018012903A
Other languages
English (en)
Inventor
Tae Choi Byung
Kyoung Shin Hwa
Whan Hong Ki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112018012903A2 publication Critical patent/BR112018012903A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a tratamento e/ou prevenção de demência, transtorno cognitivo, e depressão vascular por uma combinação de aripiprazol e cilostazol, ou semelhante. a combinação contém aripiprazol e cilostazol, e é usada para o tratamento e/ou a prevenção de no mínimo um membro selecionado entre o grupo consistindo em demência, transtorno cognitivo, e depressão vascular.
BR112018012903A 2015-12-25 2016-12-22 fármaco compreendendo aripiprazol e cilostazol BR112018012903A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015006489 2015-12-25
PCT/JP2016/088554 WO2017111123A1 (en) 2015-12-25 2016-12-22 Drug comprising aripiprazole and cilostazol

Publications (1)

Publication Number Publication Date
BR112018012903A2 true BR112018012903A2 (pt) 2018-12-11

Family

ID=59090570

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012903A BR112018012903A2 (pt) 2015-12-25 2016-12-22 fármaco compreendendo aripiprazol e cilostazol

Country Status (14)

Country Link
US (1) US20190008854A1 (pt)
EP (1) EP3393476A1 (pt)
JP (1) JP2018538344A (pt)
KR (1) KR20180097652A (pt)
CN (1) CN108430474A (pt)
AU (1) AU2016375724A1 (pt)
BR (1) BR112018012903A2 (pt)
CA (1) CA3009309A1 (pt)
MX (1) MX2018007791A (pt)
PH (1) PH12018501315A1 (pt)
RU (1) RU2018127013A (pt)
SG (1) SG11201805363QA (pt)
TW (1) TW201729809A (pt)
WO (1) WO2017111123A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112107579A (zh) * 2019-06-21 2020-12-22 澳门大学 阿立哌唑在抗衰老中的应用
US20230270737A1 (en) * 2020-05-11 2023-08-31 Shimadzu Corporation Therapeutic Agent for Mild Cognitive Impairment
CN114762688A (zh) * 2021-01-13 2022-07-19 南京宁丹新药技术有限公司 一种含有西洛他唑的组合物在脑血管病中的应用
WO2022270663A1 (ko) * 2021-06-23 2022-12-29 동아에스티 주식회사 도네페질, 실로스타졸 및 아리피프라졸을 포함하는 치매, 인지장애 또는 혈관성 우울증의 예방, 개선 또는 치료용 약학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015101100A (ru) * 2012-06-15 2016-08-10 Фаундейшн Фор Байомедикал Рисерч Энд Инновейшн Профилактическое и/или терапевтическое средство для умеренного когнитивного нарушения

Also Published As

Publication number Publication date
RU2018127013A (ru) 2020-01-27
WO2017111123A1 (en) 2017-06-29
US20190008854A1 (en) 2019-01-10
PH12018501315A1 (en) 2019-02-18
SG11201805363QA (en) 2018-07-30
CN108430474A (zh) 2018-08-21
EP3393476A1 (en) 2018-10-31
MX2018007791A (es) 2018-11-09
AU2016375724A1 (en) 2018-07-12
KR20180097652A (ko) 2018-08-31
TW201729809A (zh) 2017-09-01
JP2018538344A (ja) 2018-12-27
CA3009309A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
HK1254665A1 (zh) 預防、改善或治療退行性腦病或認知功能障礙的新型乳酸菌和組合物
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001367A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
BR112018011709A2 (pt) inibidores bicíclicos de pad4
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
BR112016028255A2 (pt) agentes imunorreguladores
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EP3501527A4 (en) COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER, CONTAINING A VESICLE DERIVED FROM BACTERIA OF A SPECIES ACTOBACILLUS
BR112017008714A2 (pt) inibidores de bromodomínio
WO2015142001A3 (ko) 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
BR112019003172A2 (pt) frações de plasma sanguíneo como tratamento para distúrbios cognitivos associados ao envelhecimento
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112018012903A2 (pt) fármaco compreendendo aripiprazol e cilostazol
BR112017017060A2 (pt) ?tratamento?
GB201611712D0 (en) Methods and compounds for the treatment or prevention of severe or persistent influenza
SG11201700530PA (en) Agent for improving brain function and agent for preventing or treating cognitive impairment
ZA201707951B (en) Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases
ZA201805407B (en) Composition for the prevention or treatment of neurodegenerative diseases.
IL275573A (en) Methods and preparations for the treatment of hypercytokinemia and severe influenza or for their prevention
ZA202000354B (en) Novel braf inhibitors and use thereof for treatment of cutaneous reactions
BR112018076619A2 (pt) composições antimalariais e usos das mesmas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2555 DE 24/12/2019.

B350 Update of information on the portal [chapter 15.35 patent gazette]